Betashares Global Healthcare Currency Hedged ETF (DRUG) Review & Analysis
- β0.4% in September (total return), behind the median international shares ETF at +0.0%.
- Investors withdrew a net $0.9m (-0.5% of the fund).
- The unit price closed the month at $9.00, 3% below its 12-month high (range $7.64 to $9.27).
About DRUG
DRUG is an international shares ETF from Betashares, listed on the ASX since August 2016. With $173m under management it is number 112 of 254 international shares ETFs by size. The management fee is 0.57% a year, about $57 on every $10,000 invested, dearer than the typical international shares ETF at 0.55%.
Its largest holdings are Eli Lilly & Co, Johnson & Johnson and AbbVie Inc, and the top 10 make up 53% of the fund. By sector it leans towards health care (95%) and information technology (4%). United States is the biggest country exposure at 81%.
Over five years it has returned +4.9% a year including distributions, against +8.8% for the median international shares ETF. With its focus on healthcare, it is the kind of fund many investors use as a smaller satellite holding alongside a diversified core.
DRUG distributions and dividend dates
DRUG pays distributions yearly, usually going ex-distribution in July, with payment about 15 days after the ex-date. (Pattern estimated from recent payments.)
The latest distribution was $0.3121 per unit (0% franked), ex-distribution on 1 July 2026 and paid on 16 July 2026. To receive it you need to own DRUG before the ex-date.
Its distribution yield over the past 12 months is about 3.5%. Distributions vary and past payments are not a guide to future ones.
From ASX announcements, updated nightly. See every ETF in the dividend calendar.
Compare DRUG with
| Fee | 0.57% | 0.41% |
| 1 year | +21.1% | +14.9% |
| 5 yrs p.a. | +4.9% | +5.9% |
| Size | $173m | $1.5bn |
| Fee | 0.57% | 0.21% |
| 1 year | +21.1% | +17.1% |
| 5 yrs p.a. | +4.9% | +10.8% |
| Size | $173m | $7.9bn |
| Fee | 0.57% | 0.10% |
| 1 year | +21.1% | +15.4% |
| 5 yrs p.a. | +4.9% | +10.9% |
| Size | $173m | $4.3bn |
| Fee | 0.57% | 0.36% |
| 1 year | +21.1% | +18.2% |
| 5 yrs p.a. | +4.9% | β |
| Size | $173m | $4.2bn |
DRUG price by TradingView
| Stock Code | DRUG |
|---|---|
| Fund Manager | Betashares |
| Asset Class | International shares |
| AUM | $173m |
| MER (%) | 0.57% |
| Net flows (Sep) | β$0.9m |
| Last Price | $9.00 |
| 52-Week Range | $7.64 β $9.27 |
| Bid/Ask Spread | 0.18% |
| Listing Date | 08/08/2016 |
| Exchange | ASX |
| Index | Not yet in our data. See the PDS |
| Issuer website | Betashares β |
Performance (% return)
$10,000 investedβ¦
Value at 30 September 2026 with distributions reinvested, before tax and brokerage.
Total returns including distributions, to 30 September 2026. 1M, 1Y, 3Y and 5Y bars are cumulative.